Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
SG

OTC · SGIOY

Shionogi & Co., Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

$9.52

Up+$0.08 (+0.85%)

Updated Nov 1, 2026, 7:22 PM

SID Score

6.3/10

Composite research score

Smart Money

46/100

Neutral

Market cap
14.53B
P/E ratio
13.35
Dividend yield
2.12%
52-week range
— – —
Volume
1.92K
Avg. volume
100.96K

Price performance · SGIOY

SGIOY price history

1M range · 0 trading sessions · Daily adjusted prices

SGIOY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest SGIOY news

The latest Smart Investors Daily articles mentioning SGIOY.

Stock researchCompany · Overview

SGIOY research

Overview

Company profile and research snapshot.

Company profile

SHIONOGI & CO UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 27, 2026

Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors

Dr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE: OGN) He joins Entera with two decades of clinical development, regulatory execution, and women’s health leadership with roles at Myovant, Shionogi and Merck prior to Organon TEL AVIV, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of clinical l

Yahoo · Oct 25, 2026

How Investors Are Reacting To Shionogi (TSE:4507) Clinical Trial Results

Shionogi reported a series of positive IDWeek 2026 updates, including Phase 3 data for XOCOVA in COVID-19 post-exposure prophylaxis, new U.S. and global evidence for Fetroja in resistant Gram-negative infections, and non-inferiority Phase 3 results for oral olorofim in invasive aspergillosis. The breadth of late-stage and real-world data across antivirals, antibiotics and antifungals underscores Shionogi's focus on high medical-need infections and highlights the depth of its commercial and...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By